PCI in T2DM: more frequent In-stent Restenosis in Patients with poor glycemic Control?

被引：0
|
作者：
Dahm, Johannes B.
机构：
来源：
AKTUELLE KARDIOLOGIE | 2024年 / 13卷 / 05期
关键词：
D O I：
10.1055/a-2388-9298
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The influence of glycemia control on the risk of stent failure in patients with type 2 diabetes (T2 D) is currently unknown. Hyperglycemia is a key factor in the development of restenosis due to hyperglycemia-induced endothelial dysfunction and excessive production of reactive oxygen species. The aim of this study was to investigate whether poor glycemia control is associated with a higher risk of stent failure in patients with T2 D.
引用
收藏
页码：350 / 350
页数：1
相关论文
共 50 条
  • [21] Intensive glycemic control reduces in-stent restenosis in diabetic patients presenting with acute coronary syndrome or symptomatic angina
    Becker, Matthew C.
    Zimbwa, Peter
    Chen, Stephen Y.
    Anwaruddin, Sail
    Galla, John M.
    Kapadia, Samir
    Krasuski, Richard A.
    CIRCULATION, 2006, 114 (18) : 395 - 395
  • [22] The effects of gastric electrical stimulation (TANTALUS®) on glycemic control in obese patients with type 2 diabetes (T2DM)
    Bohdjalian, Arthur
    Rosak, Ch
    Jung, R.
    Schramm, M.
    Weiner, R.
    Ludvik, B.
    Prager, G.
    OBESITY SURGERY, 2007, 17 (08) : 1055 - 1055
  • [23] Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)
    Kadowaki, Takashi
    Haneda, Masakazu
    Inagaki, Nobuya
    Taniguchi, Atsushi
    Sakamoto, Masashi
    Koiwai, Kazuki
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A297 - A298
  • [24] Dapagliflozin Improves Glycemic Control and Reduces Body Weight in Patients With T2DM across the Treatment Continuum
    Salsali, Afshin
    Wei, Li
    Wessman, Catrin
    Hardy, Elise
    Ptaszynska, Agata
    Parikh, Shamik
    DIABETES, 2012, 61 : A593 - A594
  • [25] Switching to Insulin Degludec Improves Glycemic Control in Patients with T2DM in a Real-World Setting
    Schultes, Bernd
    Tentolouris, Nikolaos
    Knudsen, Soren T.
    Lapolla, Annunziata
    Eidenmueller, Markus
    Prager, Rudolf
    Phan, Tra-Mi
    Wolden, Michael L.
    Siegmund, Thorsten
    DIABETES, 2017, 66 : A266 - A266
  • [26] Accelerated Insulin PK and Improved Glycemic Control in T2DM Patients by Coinjection of Prandial Insulin with Hyaluronidase
    Hompesch, Marcus
    Muchmore, Douglas
    Morrow, Linda
    Ludington, Elizabeth
    Vaughn, Daniel
    DIABETES, 2010, 59 : A103 - A103
  • [27] Gastric banding improves short- and long-term glycemic control in T2DM patients
    Fried, M.
    Owen, K.
    Dolezalova, K.
    OBESITY SURGERY, 2008, 18 (04) : 456 - 456
  • [28] ASSOCIATION ANALYSIS OF DIABETES TREATMENT, GLYCEMIC CONTROL, AND COMPLICATIONS AMONG T2DM PATIENTS IN THE UNITED STATES
    Abegaz, T.
    Fatimah, S.
    VALUE IN HEALTH, 2022, 25 (07) : S592 - S593
  • [29] Lixisenatide Added to Basal Insulin Reduces Glycemic Variability in T2DM Patients
    Umpierrez, Guillermo E.
    Digenio, Andres
    Goldenberg, Ronald
    Hernandez-Triana, Eric
    Lin, Jay
    O'Neal, David
    Park, Cheol-Young
    Renard, Eric
    Kovatchev, Boris
    DIABETES, 2014, 63 : A260 - A260
  • [30] Achieving Postprandial Glucose Control with Lixisenatide (LIXI) Improves Glycemic Control in T2DM Patients (Pts) on Basal Insulin
    Davidson, Jaime A.
    Stager, William
    Paranjape, Sachin
    Berria, Rachele
    Leiter, Lawrence A.
    DIABETES, 2015, 64 : A299 - A299
12345